Select your country

Nidda Healthcare GmbH intends to conduct a squeeze-out of minority shareholders in STADA Arzneimittel AG under stock corporation law

  • 08/06/2020
  • Press Release

Bad Vilbel, June 8, 2020 – Nidda Healthcare GmbH has informed the management board of STADA Arzneimittel AG on 5th June that it holds in total 60,886,128 shares and thus around 97.7 percent of STADA Arzneimittel AG.

In line with usual practice in comparable situations, Nidda Healthcare GmbH has notified the management board of its intention, through convening an extraordinary general meeting, to transfer shares from the company’s remaining shareholders to Nidda Healthcare GmbH in return for offering a fair cash compensation (squeeze-out under Section 327a of the German Stock Corporation Action).

The transfer of the shares of the remaining shareholders needs to be approved by an extraordinary general meeting. Assuming the meeting is called, it is expected to be held during the second half of 2020. The amount of the cash compensation will be determined by Nidda Healthcare GmbH and confirmed by a court-appointed expert auditor.


About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two-pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. As of December 31, 2019, STADA employed 11,100 people worldwide.

Additional information for journalists
STADA Arzneimittel AG
Media Relations
Stadastrasse 2-18
61118 Bad Vilbel - Germany
Phone: +49 (0) 6101 603-165
Fax: +49 (0) 6101 603-215

Additional information for capital market participants
STADA Arzneimittel AG
Investor & Creditor Relations
Stadastrasse 2-18
61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-4689
Fax: +49 (0) 6101 603-215